Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

D Finzi, M Hermankova, T Pierson, LM Carruth, C Buck… - Science, 1997 - science.org
D Finzi, M Hermankova, T Pierson, LM Carruth, C Buck, RE Chaisson, TC Quinn
Science, 1997science.org
The hypothesis that quiescent CD4+ T lymphocytes carrying proviral DNA provide a
reservoir for human immunodeficiency virus–type 1 (HIV-1) in patients on highly active
antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated
with HAART for up to 30 months, replication-competent virus was routinely recovered from
resting CD4+ T lymphocytes. The frequency of resting CD4+ T cells harboring latent HIV-1
was low, 0.2 to 16.4 per 106 cells, and, in cross-sectional analysis, did not decrease with …
The hypothesis that quiescent CD4+ T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus–type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes. The frequency of resting CD4+ T cells harboring latent HIV-1 was low, 0.2 to 16.4 per 106 cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4+ T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.
AAAS